Objective: To investigate the potential targets and molecular mechanisms of paeoniflorin in treating depression using network pharmacology. Methods: Targets of paeoniflorin were predicted via the Swiss Target Prediction database. Depression-related targets were obtained from the GeneCards database, and an intersection of "drug-disease" targets was constructed. A protein-protein interaction (PPI) network was built using the STRING platform, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses (P < 0.05) via DAVID. Results: Twenty-four paeoniflorin targets and 5,443 depression-related targets were identified, yielding 15 intersection targets. The PPI network contained 11 nodes and 18 edges, with core targets including FGF2, HSP90AA1, and others. GO enrichment analysis revealed: biological processes (BP) involving wound healing, cell chemotaxis, and regulation of body fluid levels; cellular components (CC) enriched in cytoplasmic vesicle lumen and platelet alpha granule; molecular functions (MF) associated with heparin binding and glycosaminoglycan binding. KEGG pathway analysis highlighted significant enrichment in PI3K-Akt signaling pathway, Rap1 signaling pathway, and Ras signaling pathway. Conclusion: Paeoniflorin exerts antidepressant effects through multitargets and multipathways, providing a theoretical basis for its therapeutic application in depression.
Published in | International Journal of Chinese Medicine (Volume 8, Issue 2) |
DOI | 10.11648/j.ijcm.20240802.11 |
Page(s) | 15-20 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
Paeoniflorin, Depression, Network Pharmacology, Enrichment Analysis, Mechanism Study
[1] | Hollon S D. What we got wrong about depression and its treatment [J]. Behaviour Research and Therapy, 2024, 180: 104599. |
[2] | Park L T, Carlos A Zarate J. Depression in the primary care setting [J]. The New England journal of medicine, 2019, 380(6): 559. |
[3] | Braillon A, Fried E I, Cristea I A, et al. Treatments for major depression [J]. Lancet (London, England), 2023, 401(10394): 2110. |
[4] | Borbély É, Simon M, Fuchs E, et al. Novel drug developmental strategies for treatment-resistant depression [J]. British Journal of Pharmacology, 2022, 179(6): 1146-1186. |
[5] | Sun Xinru, Li Junling, Zhou Huiwen, et al. Origin and research progress of traditional Chinese medicine prescription treatment for depression [J]. Journal of Traditional Chinese Medicine Literature, 2024, 42(6): 100-104. |
[6] | Shen Zixin, Mou Chunyan, Zhou Xueer, et al. Research Progress on the Pharmacological Effects of Paeonia alba and Its Chemical Components [J]. Jiangsu Journal of Traditional Chinese Medicine, 2024, 56(8): 76-79. |
[7] | Li Zehao, Wu Shuang, Liu Lin, et al. Study on Antidepressant Pharmacodynamic Substances Based on the Correlation between Substance and Efficacy [J]. Chinese Herbal Medicine, 2024, 55(24): 8353-8365. |
[8] | Fu Chunyan, Chen Yu, Liu Yonghui, et al. Exploring the mechanism of lily in the treatment of depression based on network pharmacology and molecular docking technology [J]. Journal of Shaoyang University (Natural Science Edition), 2024, 21(6): 105-116. |
[9] | Liu Y, Li Bairui, Li Yongcai, et al. Jiawei Xiaoyao Pill Improves Depression-like Behavior in Rats through Neurotransmitter Regulation, Anti-inflammatory and Antioxidant and Intestinal Microbiota Regulation [J]. Journal of Southern Medical University, 2025. 45(02): 347-358. |
[10] | Tang M M, Lin W J, Zhang J T, et al. Exogenous FGF2 reverses depressive-like behaviors and restores the suppressed FGF2-ERK1/2 signaling and the impaired hippocampal neurogenesis induced by neuroinflammation [J]. Brain, Behavior, and Immunity, 2017, 66: 322-331. |
[11] | F B, M K, M C, et al. Genetic and stress-induced loss of NG2 glia triggers emergence of depressive-like behaviors through reduced secretion of FGF2 [J]. Neuron, 2019, 104(4). |
[12] | Yj Q, Yr L, Lg S, et al. Distinct proteomic profiles in prefrontal subareas of elderly major depressive disorder and bipolar disorder patients [J]. Translational psychiatry, 2022, 12(1). |
[13] | N G, X W, M X, et al. PI3K/AKT signaling pathway: Molecular mechanisms and therapeutic potential in depression [J]. Pharmacological research, 2024, 206. |
[14] | Wang X L, Wang Y T, Guo Z Y, et al. Efficacy of paeoniflorin on models of depression: A systematic review and meta-analysis of rodent studies [J]. Journal of Ethnopharmacology, 2022, 290: 115067. |
[15] | C T, Y W, H H. Unraveling the link between heavy metals, perfluoroalkyl substances and depression: Insights from epidemiological and bioinformatics strategies [J]. Ecotoxicology and environmental safety, 2024, 279. |
APA Style
Zhang, J., Li, K., Xie, X., Ding, H., Wang, X., et al. (2025). A Multi-target Mechanism Study of Paeoniflorin in the Treatment of Depression Based on Network Pharmacology. International Journal of Chinese Medicine, 8(2), 15-20. https://doi.org/10.11648/j.ijcm.20240802.11
ACS Style
Zhang, J.; Li, K.; Xie, X.; Ding, H.; Wang, X., et al. A Multi-target Mechanism Study of Paeoniflorin in the Treatment of Depression Based on Network Pharmacology. Int. J. Chin. Med. 2025, 8(2), 15-20. doi: 10.11648/j.ijcm.20240802.11
@article{10.11648/j.ijcm.20240802.11, author = {Jing Zhang and Keming Li and Xinjing Xie and Hailing Ding and Xuehui Wang and Yihui Li and Xing Gao and Jinlong Han}, title = {A Multi-target Mechanism Study of Paeoniflorin in the Treatment of Depression Based on Network Pharmacology }, journal = {International Journal of Chinese Medicine}, volume = {8}, number = {2}, pages = {15-20}, doi = {10.11648/j.ijcm.20240802.11}, url = {https://doi.org/10.11648/j.ijcm.20240802.11}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcm.20240802.11}, abstract = {Objective: To investigate the potential targets and molecular mechanisms of paeoniflorin in treating depression using network pharmacology. Methods: Targets of paeoniflorin were predicted via the Swiss Target Prediction database. Depression-related targets were obtained from the GeneCards database, and an intersection of "drug-disease" targets was constructed. A protein-protein interaction (PPI) network was built using the STRING platform, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses (P < 0.05) via DAVID. Results: Twenty-four paeoniflorin targets and 5,443 depression-related targets were identified, yielding 15 intersection targets. The PPI network contained 11 nodes and 18 edges, with core targets including FGF2, HSP90AA1, and others. GO enrichment analysis revealed: biological processes (BP) involving wound healing, cell chemotaxis, and regulation of body fluid levels; cellular components (CC) enriched in cytoplasmic vesicle lumen and platelet alpha granule; molecular functions (MF) associated with heparin binding and glycosaminoglycan binding. KEGG pathway analysis highlighted significant enrichment in PI3K-Akt signaling pathway, Rap1 signaling pathway, and Ras signaling pathway. Conclusion: Paeoniflorin exerts antidepressant effects through multitargets and multipathways, providing a theoretical basis for its therapeutic application in depression. }, year = {2025} }
TY - JOUR T1 - A Multi-target Mechanism Study of Paeoniflorin in the Treatment of Depression Based on Network Pharmacology AU - Jing Zhang AU - Keming Li AU - Xinjing Xie AU - Hailing Ding AU - Xuehui Wang AU - Yihui Li AU - Xing Gao AU - Jinlong Han Y1 - 2025/05/24 PY - 2025 N1 - https://doi.org/10.11648/j.ijcm.20240802.11 DO - 10.11648/j.ijcm.20240802.11 T2 - International Journal of Chinese Medicine JF - International Journal of Chinese Medicine JO - International Journal of Chinese Medicine SP - 15 EP - 20 PB - Science Publishing Group SN - 2578-9473 UR - https://doi.org/10.11648/j.ijcm.20240802.11 AB - Objective: To investigate the potential targets and molecular mechanisms of paeoniflorin in treating depression using network pharmacology. Methods: Targets of paeoniflorin were predicted via the Swiss Target Prediction database. Depression-related targets were obtained from the GeneCards database, and an intersection of "drug-disease" targets was constructed. A protein-protein interaction (PPI) network was built using the STRING platform, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses (P < 0.05) via DAVID. Results: Twenty-four paeoniflorin targets and 5,443 depression-related targets were identified, yielding 15 intersection targets. The PPI network contained 11 nodes and 18 edges, with core targets including FGF2, HSP90AA1, and others. GO enrichment analysis revealed: biological processes (BP) involving wound healing, cell chemotaxis, and regulation of body fluid levels; cellular components (CC) enriched in cytoplasmic vesicle lumen and platelet alpha granule; molecular functions (MF) associated with heparin binding and glycosaminoglycan binding. KEGG pathway analysis highlighted significant enrichment in PI3K-Akt signaling pathway, Rap1 signaling pathway, and Ras signaling pathway. Conclusion: Paeoniflorin exerts antidepressant effects through multitargets and multipathways, providing a theoretical basis for its therapeutic application in depression. VL - 8 IS - 2 ER -